|
 |
| EDITORIAL |
|
|
|
| Year : 2014 | Volume
: 24
| Issue : 3 | Page : 139-140 |
| |
Cost of treating diabetic kidney disease
I Dasgupta
Renal Unit, Birmingham Heartlands Hospital, and School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom
| Date of Web Publication | 6-May-2014 |
Correspondence Address:
I Dasgupta
Renal unit, Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS
United Kingdom
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0971-4065.131999
How to cite this article:
Dasgupta I. Cost of treating diabetic kidney disease. Indian J Nephrol 2014;24:139-40 |
We are in the midst of a global epidemic of type 2 diabetes. Currently, there are more than 371 million people with diabetes in the world and it is estimated to grow to 552 million by the year 2030, of which 101 million will be in India. [1] Diabetic kidney disease (DKD) is the most common cause of end stage kidney disease (ESKD) both in the developed and the developing world accounting for 20-40% of patients starting renal replacement therapy; [2] in India, 31% of the ESKD population have DKD. [3] This figure is likely to rise steadily over the next 2 decades.
The humanistic, societal and economic impact of DKD is enormous. In addition to seriously affecting physical health and quality-of-life of the patients, it has disruptive and permanent implications on their identity, emotions, family, life-style, relationships and employment. It places a huge economic burden on the health-care system; e.g., a cost of illness study carried out in the last decade estimated that the total annual cost to the National Health Service in the UK was ͳ685 million ($1.5 billion) and the total annual medical cost to all payers in the US was $16.8 billion. [4] Moreover, kidney disease accounts for most of the excess death in type 2 diabetics. [5]
In this issue of the journal Satyavani et al. [6] have looked at the direct cost of treating chronic kidney disease (CKD) in type 2 diabetics in India. The authors assessed comparative cost of treatment of diabetics without CKD, those with Stage 1-4 CKD, those needing dialysis and those with kidney transplantation. They determined cost of treatment at two levels: Cost of hospitalization and total cost of treatment over the previous 2 years taking into account costs of hospitalization, consultation, medication, laboratory tests, dialysis treatment, transplantation surgery and transportation. Unsurprisingly, treatment of diabetics with ESKD incurred very high expenditure - on average INR 500,000 ($10,753) for a dialysis patient and INR 345,000 ($7,419) for a transplant patient over a 2 year period. Over the same period, the average cost of treatment of diabetics with and without CKD were INR 100,000 ($2150) and 30,000 ($645) respectively. Nearly 80% of all patients had a family income of INR 20,000 or less a month and INR 10,000 or less in 40%. Only 23% had medical insurance to cover the costs of treatment and the rest were out of pocket expenditure. These figures put the actual cost of treatment of DKD in context. By the authors' own admission, there are several limitations of this study including the small sample size and the data collected from a specialized diabetes center and a private hospital limiting the generalizability of the results to certain private sector health-care organizations only. However, it does provide an estimate of the financial cost of treating DKD in Indian setting.
In the absence of state funded medical treatment and medical insurance cover, in a developing country like India, patients with CKD/ESKD often have to take loans, mortgage or sale properties in order to pay for treatment. There is also the issue of access to treatment; in India most of the dialysis and kidney transplant centers are in the private sector. [7] The high cost of treatment in such centers makes treatment unaffordable to most. Ramachandran and Jha have recently demonstrated that even kidney transplantation, the most cost-effective form of renal replacement therapy, in a public sector hospital can have catastrophic financial consequences pushing the majority of families into severe poverty. [8] Given the magnitude of the problem we are facing, the exponentially rising prevalence of DKD and the consequent economic impact, "the only practical solution for India, just as it would be for any other country," will be putting more effort in preventing and delaying progression of diabetic nephropathy. [2],[7]
DKD is preventable. There is substantial evidence that early and effective therapeutic intervention in type 2 diabetes can prevent DKD, and retard progression of established DKD. Strict glycemic and blood pressure control can reduce the incidence and slow progression of DKD. [9],[10] Inhibition of the renin angiotensin system decrease progression from normoalbuminuria to microalbuminuria, microalbuminuria to macroalbuminuria and the development of ESKD. [11],[12],[13] A number of new agents are being trialed that may in future be able to reduce renal damage and fibrosis. [2]
The study by Satyavani et al. not only gives us an estimate of the direct cost of treating renal complications in type 2 diabetics in India, it also brings home the importance of preventing such complications and emphasizes the need for developing cost-effective strategies to treat DKD.
| References | |  |
| 1. | International Diabetes Federation. International Diabetes Federation Atlas. 5 th ed. Brussels, Belgium: International Diabetes Federation; 2011. Available from: http://www.idf.org/diabetesatlas. [Last accessed on 2014 Sep 13]. 
|
| 2. | Atkins RC, Zimmet P. Diabetic kidney disease: Act now or pay later. Nephrol Dial Transplant 2010;25:331-3.
|
| 3. | Rajapurkar MM, John GT, Kirpalani AL, Abraham G, Agarwal SK, Almeida AF, et al. What do we know about chronic kidney disease in India: First report of the Indian CKD registry. BMC Nephrol 2012;13:10.
|
| 4. | Gordois A, Scuffham P, Shearer A, Oglesby A. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications 2004;18:18-26.
|
| 5. | Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013;24:302-8.
|
| 6. | Satyavani K, Kothandan H, Jayaraman M, Viswanathan V. Direct costs associated with chronic kidney disease among type 2 diabetic patients in India. Indian J Nephrol. 2014; 24:141-7.
|
| 7. | Agarwal SK. Chronic kidney disease and its prevention in India. Kidney Int Suppl 2005;24:S41-5.
|
| 8. | Ramachandran R, Jha V. Kidney transplantation is associated with catastrophic out of pocket expenditure in India. PLoS One 2013;8:e67812.
|
| 9. | Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
|
| 10. | Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care 2009;32:2068-74.
|
| 11. | Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.
|
| 12. | Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
|
| 13. | Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
|
| This article has been cited by | | 1 |
The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy |
|
| Jennifer Rose Matthews, Markus P. Schlaich, Elizabeth Piroska Rakoczy, Vance Bruce Matthews, Lakshini Yasaswi Herat | | Biomedicines. 2022; 10(3): 522 | | [Pubmed] | [DOI] | | | 2 |
ERK and p38 MAPK inhibition controls NF-E2 degradation and profibrotic signaling in renal proximal tubule cells |
|
| Jia Li, Shunying Jin, Michelle T. Barati, Sanjana Rane, Qian Lin, Yi Tan, Lu Cai, Madhavi J. Rane | | Life Sciences. 2021; 287: 120092 | | [Pubmed] | [DOI] | | | 3 |
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG Outcome Trial |
|
| Odette S. Reifsnider, Anuraag R. Kansal, Christoph Wanner, Egon Pfarr, Audrey Koitka-Weber, Sarah B. Brand, Matthew Stargardter, Cheng Wang, Effie Kuti, Anastasia Ustyugova | | American Journal of Kidney Diseases. 2021; | | [Pubmed] | [DOI] | | | 4 |
EFFECT OF TARAKESWARA RASA IN MICROALBUMINURIA ASSOCIATED WITH TYPE (II) DIABETES MELLITUS - A CLINICAL STUDY |
|
| Krishnaveni. R, Jacob. M. Titus, Sreeni T.V. | | International Ayurvedic Medical Journal. 2021; p5(02): 2671 | | [Pubmed] | [DOI] | | | 5 |
Intraglomerular Monocyte/Macrophage Infiltration and Macrophage–Myofibroblast Transition during Diabetic Nephropathy Is Regulated by the A2B Adenosine Receptor |
|
| Ángelo Torres, Katherin Muñoz, Yessica Nahuelpán, Angelo-Paolo R. Saez, Pablo Mendoza, Claudia Jara, Claudio Cappelli, Raibel Suarez, Carlos Oyarzún, Claudia Quezada, Rody San Martín | | Cells. 2020; 9(4): 1051 | | [Pubmed] | [DOI] | |
|
|
|
|
|
|
|
|
|
Editorial Board
